Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...
Most recently, Amgen faced the kind of legal challenges normally reserved for big pharma, with allegations of allegedly violating anti-kickback rules by “overfilling” Aranesp vials.
Less than a decade since it secured its first FDA approval for a biosimilar, Amgen’s portfolio of the copycat drugs is growing and making strong contributions to the company’s top line.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback